Literature DB >> 9290362

Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye.

N Yokoi1, A Komuro, K Nishida, S Kinoshita.   

Abstract

AIMS/
BACKGROUND: The aim of this study was to assess quantitatively the effectiveness of hyaluronan on corneal disruption in patients with dry eye. Corneal epithelial barrier function was evaluated by measuring fluorescein permeability using a slit-lamp fluorophotometer.
METHODS: 11 patients with dry eye were assigned to this study. Hyaluronan ophthalmic solution (0.1% hyaluronic acid) was instilled five times a day to the right eye, in addition to the usual artificial tear solutions. The left eye received only the artificial tear solutions. Corneal barrier function was evaluated on the pretreatment day, and at 2 and 4 weeks after treatment. Fluorophotometry was used to measure fluorescein uptake at the central and lower corneal portions.
RESULTS: Two weeks after treatment, hyaluronan treated right corneas showed significant corneal epithelial barrier improvement in the lower portion, compared with the pretreatment day (p < 0.025). Four weeks after treatment, the treated corneas showed significant improvement in the central corneal portion (p < 0.025) and improvement in the lower portion, compared with the pretreatment day. The untreated left corneas, on the other hand showed no improvement during the course of the study.
CONCLUSION: This study suggests that hyaluronan is effective in the treatment of corneal epithelial disruption in dry eye.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290362      PMCID: PMC1722248          DOI: 10.1136/bjo.81.7.533

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  Topical application of hyaluronic acid and chondroitin sulfate in the treatment of dry eyes.

Authors:  M B Limberg; C McCaa; G E Kissling; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

2.  The effect of sodium hyaluronate on the corneal epithelium. An ultrastructural study.

Authors:  Y S Wysenbeek; N Loya; I Ben Sira; I Ophir; Y Ben Shaul
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-02       Impact factor: 4.799

3.  Sjögren's syndrome. Proposed criteria for classification.

Authors:  R I Fox; C A Robinson; J G Curd; F Kozin; F V Howell
Journal:  Arthritis Rheum       Date:  1986-05

4.  Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes.

Authors:  L S Mengher; K S Pandher; A J Bron; C C Davey
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

5.  Diagnostic tests in the Sicca syndrome.

Authors:  O P van Bijsterveld
Journal:  Arch Ophthalmol       Date:  1969-07

6.  Artificial tear solutions.

Authors:  M A Lemp
Journal:  Int Ophthalmol Clin       Date:  1973

7.  A clinical study of slow-releasing artificial tears.

Authors:  D W Lamberts; D P Langston; W Chu
Journal:  Ophthalmology       Date:  1978-08       Impact factor: 12.079

8.  The protective effect of Na-hyaluronate to corneal endothelium.

Authors:  E L Graue; F M Polack; E A Balazs
Journal:  Exp Eye Res       Date:  1980-07       Impact factor: 3.467

9.  Sodium hyaluronate eyedrops in the treatment of dry eyes.

Authors:  S Shimmura; M Ono; K Shinozaki; I Toda; E Takamura; Y Mashima; K Tsubota
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

10.  Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca.

Authors:  J D Nelson; R L Farris
Journal:  Arch Ophthalmol       Date:  1988-04
View more
  23 in total

1.  Cytotoxicity assays of new artificial tears containing 2-methacryloyloxyethyl phosphorylcholine polymer for ocular surface cells.

Authors:  Masahiko Ayaki; Atsuo Iwasawa; Yoshimi Niwano
Journal:  Jpn J Ophthalmol       Date:  2011-08-10       Impact factor: 2.447

Review 2.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

3.  A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients.

Authors:  M Nakahara; K Miyata; S Otani; T Miyai; R Nejima; S Yamagami; S Amano
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

Review 4.  Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues.

Authors:  Benjamin G Cooper; Ara Nazarian; Brian D Snyder; Mark W Grinstaff
Journal:  Biomaterials       Date:  2018-07-26       Impact factor: 12.479

5.  Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome.

Authors:  P I Condon; C G McEwen; M Wright; G Mackintosh; R J Prescott; C McDonald
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

6.  Hyaluronan impairs the barrier integrity of brain microvascular endothelial cells through a CD44-dependent pathway.

Authors:  Abraham J Al-Ahmad; Ronak Patel; Sean P Palecek; Eric V Shusta
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-28       Impact factor: 6.200

7.  Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.

Authors:  N Yokoi; Y Sonomura; H Kato; A Komuro; S Kinoshita
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

8.  Cathepsin S is a novel target for age-related dry eye.

Authors:  Zhiyuan Yu; Jinmiao Li; Gowthaman Govindarajan; Sarah F Hamm-Alvarez; Jehan Alam; De-Quan Li; Cintia S de Paiva
Journal:  Exp Eye Res       Date:  2021-12-12       Impact factor: 3.467

Review 9.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

10.  Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients.

Authors:  P Aragona; G Di Stefano; F Ferreri; R Spinella; A Stilo
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.